Were it business opportunities or hidden risks: Observations on clinical trials and marketing authorizations of Gilead Science's remdesivir in China.
Pharmazie
; 75(8): 407-410, 2020 08 01.
Article
in English
| MEDLINE | ID: covidwho-696997
ABSTRACT
New drugs against the in COVID-19 pandemic are urgently needed. Gilead Science's remdesivir has been introduced to China through special approval procedures, and was directly conducting the Phase III clinical trial. As expected, the marketing authorization process was completed soon. The drug brought hope to patients as well as business opportunities to companies. However, we must pay attention to the patent competition, generic drug competition and other unfair competition that remdesivir may face in China. China also needs to strengthen the innovation ability and international cooperation ability of local pharmaceutical companies by taking advantages of the opportunity to introduce remdesivir.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Antiviral Agents
/
Pneumonia, Viral
/
Adenosine Monophosphate
/
Coronavirus Infections
/
Alanine
Type of study:
Observational study
/
Prognostic study
/
Randomized controlled trials
Limits:
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Pharmazie
Journal subject:
Pharmacy
Year:
2020
Document Type:
Article
Affiliation country:
Ph.2020.0549
Similar
MEDLINE
...
LILACS
LIS